产品名称
MB49小鼠膀胱癌细胞系, MB49 mouse urothelial carcinoma cell line is widely used as an in vitro and in vivo model of bladder cancer.
biological source
mouse
technique(s)
cell culture | mammalian: suitable
shipped in
ambient
Analysis Note
• 每小瓶含有≥ 1X106个活细胞。
• Charles River动物诊断服务通过小鼠Essential CLEAR小组对细胞进行传染病检测，结果为阴性。
• 通过Charles River动物诊断服务的污染透明小组评估，证实细胞为小鼠来源，对大鼠、中国仓鼠、金色黄叙利亚仓鼠、人和非人灵长类动物（NHP）的种间污染物呈阴性。
• 细胞对支原体污染呈阴性
• Charles River动物诊断服务通过小鼠Essential CLEAR小组对细胞进行传染病检测，结果为阴性。
• 通过Charles River动物诊断服务的污染透明小组评估，证实细胞为小鼠来源，对大鼠、中国仓鼠、金色黄叙利亚仓鼠、人和非人灵长类动物（NHP）的种间污染物呈阴性。
• 细胞对支原体污染呈阴性
General description
MB49细胞来自C57BL/Icrf-a’小鼠膀胱上皮细胞，在长期原代培养的第二天经化学致癌物7, 12-二甲苯[a]蒽（DMBA）单独处理24小时后转化。 经证实，移植到同基因鼠体内的转化细胞可诱发癌症。 而对父系起源，核型分析表明Y染色体在所分析的细胞中会100%丢失。 这种异常是人类膀胱癌的常见早期事件。 最近的一项研究表明，MB49细胞再现了膀胱肿瘤生长中性别差异的关键特征。 MB49植入小鼠后，雄性小鼠的肿瘤明显大于雌性小鼠。 在双氢睾酮的作用下，MB49细胞呈剂量依赖性增殖增强。 相反，MB49细胞对妊娠激素、人绒毛膜促性腺激素(hCG)无反应。MB49细胞表现为MHC-I类和II类分子的低表达或不表达。 然而，IFN-暴露后，MHC I类和II类表达显著上调。
Other Notes
根据产品文件中详述的“学术使用协议”的条款，本产品预期仅用于销售和销售给学术机构，以供内部学术研究使用。有关任何其他用途的信息，请联系licensing@emdmillipore.com。
存储类别
10 - Combustible liquids
wgk
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
Zheng Zhu et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 28(21), 4820-4831 (2022-08-04)
Immune checkpoint inhibitors (ICI) in general have shown poor efficacy in bladder cancer. The purpose of this project was to determine whether photodynamic therapy (PDT) with bladder cancer-specific porphyrin-based PLZ4-nanoparticles (PNP) potentiated ICI. SV40 T/Ras double-transgenic mice bearing spontaneous bladder
Dominik Gulyás et al.
PloS one, 17(7), e0270802-e0270802 (2022-07-09)
The basis of the antitumor immunotherapy, of which the purpose is the stimulation of the immune system. We have used two of the Pathogen Associated Molecular Patterns: unmethylated CpG oligonucleotide, a ligand of Toll-like receptor 9 (TLR9), and lipopolysaccharide (LPS)
Guangchuan Wang et al.
Cancer discovery, 10(12), 1912-1933 (2020-09-06)
Immune checkpoint blockade (ICB) has shown remarkable clinical efficacy in several cancer types. However, only a fraction of patients will respond to ICB. Here, we performed pooled mutagenic screening with CRISPR-mediated genetically engineered mouse models (CRISPR-GEMM) in ICB settings, and
Vanessa Bellat et al.
Cancer research, 82(7), 1409-1422 (2022-01-19)
The standard treatment of nonmuscle invasive bladder cancer (NMIBC) is transurethral resection of the tumors, followed by intravesical therapy (IT), which comprises a direct instillation of a solution of Bacillus Calmette-Guérin vaccine or chemotherapy into the bladder. However, the recurrence
Mathieu Rouanne et al.
The Journal of clinical investigation, 132(12) (2022-05-04)
Patients with high-risk, nonmuscle-invasive bladder cancer (NMIBC) frequently relapse after standard intravesical bacillus Calmette-Guérin (BCG) therapy and may have a dismal outcome. The mechanisms of resistance to such immunotherapy remain poorly understood. Here, using cancer cell lines, freshly resected human
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持